IDEAS home Printed from https://ideas.repec.org/a/spr/eujhec/v15y2014i1d10.1007_s10198-014-0599-z.html
   My bibliography  Save this article

Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres

Author

Listed:
  • Orsolya Balogh

    (Corvinus University of Budapest)

  • Valentin Brodszky

    (Corvinus University of Budapest)

  • László Gulácsi

    (Corvinus University of Budapest)

  • Emese Herédi

    (University of Debrecen)

  • Krisztina Herszényi

    (Semmelweis University)

  • Hajnalka Jókai

    (Semmelweis University)

  • Sarolta Kárpáti

    (Semmelweis University)

  • Petra Baji

    (Corvinus University of Budapest)

  • Éva Remenyik

    (University of Debrecen)

  • Andrea Szegedi

    (University of Debrecen)

  • Péter Holló

    (Semmelweis University)

Abstract

Background Despitethe widespread availability of biological drugs in psoriasis, there is a shortage of disease burden studies. Objectives To assess the cost-of-illness and quality of life of patients with moderate to severe psoriasis in Hungary. Methods Consecutive patients with Psoriasis Area and Severity Index (PASI) > 10 and Dermatology Life Quality Index (DLQI) > 10, or treated with traditional systemic (TST) or biological systemic treatment (BST) were included. Demographic data, clinical characteristics, psoriasis related medication, health care utilizations and employment status in the previous 12 months were recorded. Costing was performed from the societal perspective applying the human capital approach. Quality of life was assessed using DLQI and EQ-5D measures. Results Two-hundred patients were involved (females 32 %) with a mean age of 51 (SD 13) years, 103 (52 %) patients were on BST. Mean PASI, DLQI and EQ-5D scores were 8 (SD 10), 6 (SD 7) and 0.69 (SD 0.3), respectively. The mean total cost was €9,254/patient/year (SD 8,502) with direct costs accounting for 86 %. The main cost driver was BST (mean €7,339/patient/year). Total costs differed significantly across treatment subgroups, mean (SD): no systemic therapy €2,186 (4,165), TST €2,388 (4,106) and BST €15,790 (6,016) (p

Suggested Citation

  • Orsolya Balogh & Valentin Brodszky & László Gulácsi & Emese Herédi & Krisztina Herszényi & Hajnalka Jókai & Sarolta Kárpáti & Petra Baji & Éva Remenyik & Andrea Szegedi & Péter Holló, 2014. "Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 101-109, May.
    • Handle: RePEc:spr:eujhec:v:15:y:2014:i:1:d:10.1007_s10198-014-0599-z
    DOI: 10.1007/s10198-014-0599-z
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s10198-014-0599-z
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.
    File URL: https://libkey.io/10.1007/s10198-014-0599-z?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    References listed on IDEAS

    as
    1. Giovanna Raho & Daniela Mihajlova Koleva & Livio Garattini & Luigi Naldi, 2012. "The Burden of Moderate to Severe Psoriasis," PharmacoEconomics, Springer, vol. 30(11), pages 1005-1013, November.
    2. Sabine I B Steinke & Wiebke K Peitsch & Alexander Ludwig & Matthias Goebeler, 2013. "Cost-of-Illness in Psoriasis: Comparing Inpatient and Outpatient Therapy," PLOS ONE, Public Library of Science, vol. 8(10), pages 1-1, October.
    3. Koopmanschap, Marc A. & Rutten, Frans F. H. & van Ineveld, B. Martin & van Roijen, Leona, 1995. "The friction cost method for measuring indirect costs of disease," Journal of Health Economics, Elsevier, vol. 14(2), pages 171-189, June.
    Full references (including those not matched with items on IDEAS)

    Citations

    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.
    as


    Cited by:

    1. Emese Herédi & Fanni Rencz & Orsolya Balogh & László Gulácsi & Krisztina Herszényi & Péter Holló & Hajnalka Jókai & Sarolta Kárpáti & Márta Péntek & Éva Remenyik & Andrea Szegedi & Valentin Brodszky, 2014. "Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 111-119, May.

    Most related items

    These are the items that most often cite the same works as this one and are cited by the same works as this one.
    1. Orsolya Balogh & Valentin Brodszky & László Gulácsi & Emese Herédi & Krisztina Herszényi & Hajnalka Jókai & Sarolta Kárpáti & Petra Baji & Éva Remenyik & Andrea Szegedi & Péter Holló, 2014. "Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 15(1), pages 101-109, May.
    2. Iris Arends & Ute Bültmann & Willem van Rhenen & Henk Groen & Jac J L van der Klink, 2013. "Economic Evaluation of a Problem Solving Intervention to Prevent Recurrent Sickness Absence in Workers with Common Mental Disorders," PLOS ONE, Public Library of Science, vol. 8(8), pages 1-1, August.
    3. Anne Tiainen & Clas Rehnberg, 2010. "The Economic Burden of Psychiatric Disorders in Sweden," International Journal of Social Psychiatry, , vol. 56(5), pages 515-526, September.
    4. Tilling, C & Krol, M & Tsuchiya, A & Brazier, J & van Exel, J & Brouwer, W, 2009. "The impact of losses in income due to ill health: does the EQ-5D reflect lost earnings?," MPRA Paper 29837, University Library of Munich, Germany.
    5. Hanly, Paul & Ortega Ortega, Marta & Pearce, Alison & Soerjomataram, Isabelle & Sharp, Linda, 2020. "Advances in the methodological approach to friction period estimation: A European perspective," Social Science & Medicine, Elsevier, vol. 264(C).
    6. Siri Fauli & Geir Thue, 2008. "Economic consequences of near-patient test results: the case of tests for the Helicobacter Pylori bacterium in dyspepsia," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 9(3), pages 221-228, August.
    7. Jakob, 2025. "Absenteeism and Firm Performance: Evidence from Retail," Discussion Paper Series of the Max Planck Institute for Research on Collective Goods 2025_02, Max Planck Institute for Research on Collective Goods.
    8. Paul Hanly & Rebecca Maguire & Frances Drummond & Linda Sharp, 2019. "Variation in the methodological approach to productivity cost valuation: the case of prostate cancer," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 20(9), pages 1399-1408, December.
    9. Jonathan Karnon & Jill Carlton & Carolyn Czoski-Murray & Kevin Smith, 2009. "Informing disinvestment through cost-effectiveness modelling," Applied Health Economics and Health Policy, Springer, vol. 7(1), pages 1-9, March.
    10. Thomas DeLeire & Willard Manning, 2004. "Labor market costs of illness: prevalence matters," Health Economics, John Wiley & Sons, Ltd., vol. 13(3), pages 239-250, March.
    11. Tobias Effertz & Susanne Engel & Frank Verheyen & Roland Linder, 2016. "The costs and consequences of obesity in Germany: a new approach from a prevalence and life-cycle perspective," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 17(9), pages 1141-1158, December.
    12. Allison Larg & John Moss, 2011. "Cost-of-Illness Studies," PharmacoEconomics, Springer, vol. 29(8), pages 653-671, August.
    13. Klose, Thomas, 1999. "The contingent valuation method in health care," Health Policy, Elsevier, vol. 47(2), pages 97-123, May.
    14. Annie Hawton & James Shearer & Elizabeth Goodwin & Colin Green, 2013. "Squinting Through Layers of Fog: Assessing the Cost Effectiveness of Treatments for Multiple Sclerosis," Applied Health Economics and Health Policy, Springer, vol. 11(4), pages 331-341, August.
    15. Foster, Nicola & Vassall, Anna & Cleary, Susan & Cunnama, Lucy & Churchyard, Gavin & Sinanovic, Edina, 2015. "The economic burden of TB diagnosis and treatment in South Africa," Social Science & Medicine, Elsevier, vol. 130(C), pages 42-50.
    16. Antoine Bailly & Et Carole Chichignoud, 2006. "Risques Et Santé/Riesgos Y Salud," Estudios de Economia Aplicada, Estudios de Economia Aplicada, vol. 24, pages 865-874, Diciembre.
    17. Hansen, Kristian S. & Moreno-Ternero, Juan D. & Østerdal, Lars P., 2024. "Quality- and productivity-adjusted life years: From QALYs to PALYs and beyond," Journal of Health Economics, Elsevier, vol. 95(C).
    18. Marie Kruse & Jan Sørensen & Dorte Gyrd-Hansen, 2012. "Future costs in cost-effectiveness analysis: an empirical assessment," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 13(1), pages 63-70, February.
    19. James Shearer & Paul McCrone & Renee Romeo, 2016. "Economic Evaluation of Mental Health Interventions: A Guide to Costing Approaches," PharmacoEconomics, Springer, vol. 34(7), pages 651-664, July.
    20. Mennini, Francesco Saverio & Gitto, Lara, 2022. "Approaches to Estimating Indirect Costs in Healthcare: Motivations for Choice," MPRA Paper 112129, University Library of Munich, Germany.

    More about this item

    Keywords

    Psoriasis; Cost-of-illness; Quality of life; Biological treatments;
    All these keywords.

    JEL classification:

    • I19 - Health, Education, and Welfare - - Health - - - Other

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:eujhec:v:15:y:2014:i:1:d:10.1007_s10198-014-0599-z. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    If CitEc recognized a bibliographic reference but did not link an item in RePEc to it, you can help with this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.